Immuneering Reconciled Depreciation vs Cost Of Revenue Analysis

IMRX Stock

USD 2.08 0.02 0.95%

Immuneering Corp financial indicator trend analysis is infinitely more than just investigating Immuneering Corp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immuneering Corp is a good investment. Please check the relationship between Immuneering Corp Reconciled Depreciation and its Cost Of Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immuneering Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Reconciled Depreciation vs Cost Of Revenue

Reconciled Depreciation vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immuneering Corp Reconciled Depreciation account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Immuneering Corp's Reconciled Depreciation and Cost Of Revenue is -0.88. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Immuneering Corp, assuming nothing else is changed. The correlation between historical values of Immuneering Corp's Reconciled Depreciation and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Immuneering Corp are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Reconciled Depreciation i.e., Immuneering Corp's Reconciled Depreciation and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.88

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Reconciled Depreciation

Cost Of Revenue

Cost of Revenue is found on Immuneering Corp income statement and represents the costs associated with goods and services Immuneering Corp provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Immuneering Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immuneering Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immuneering Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.At this time, Immuneering Corp's Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 55.6 M in 2024, whereas Selling General Administrative is likely to drop slightly above 10.2 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	34.8M	51.9M	58.4M	37.5M
Cost Of Revenue	1.2M	158.1K	764.1K	732.6K

Total Operating Expenses Cost Of Revenue

Immuneering Corp fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Non Current Liabilities Other
Total Assets		-0.79	0.92	0.91	0.98	0.96	0.98	-0.96	-0.77	0.82	0.98	0.97	0.67	1.0	-0.42	0.94	0.64	-0.54	0.94	-0.81	-0.33	0.98	0.57	1.0	0.95	0.43
Short Long Term Debt Total	-0.79		-0.78	-0.83	-0.66	-0.67	-0.78	0.92	0.75	-0.87	-0.88	-0.76	-0.65	-0.79	0.1	-0.73	-0.62	0.01	-0.75	0.47	-0.26	-0.66	-0.63	-0.79	-0.74	-0.48
Other Current Liab	0.92	-0.78		0.99	0.92	0.95	0.98	-0.93	-0.92	0.89	0.94	0.98	0.85	0.91	-0.61	0.99	0.78	-0.6	1.0	-0.6	-0.38	0.92	0.75	0.91	0.99	0.68
Total Current Liabilities	0.91	-0.83	0.99		0.89	0.92	0.97	-0.95	-0.91	0.95	0.96	0.97	0.86	0.9	-0.58	0.97	0.76	-0.53	0.98	-0.61	-0.29	0.89	0.73	0.9	0.98	0.63
Total Stockholder Equity	0.98	-0.66	0.92	0.89		0.99	0.97	-0.89	-0.75	0.77	0.94	0.97	0.66	0.98	-0.53	0.95	0.63	-0.68	0.95	-0.82	-0.51	1.0	0.55	0.98	0.96	0.43
Net Tangible Assets	0.96	-0.67	0.95	0.92	0.99		0.98	-0.89	-0.78	0.77	0.93	0.98	0.7	0.96	-0.56	0.98	0.66	-0.68	0.97	-0.76	-0.51	0.99	0.6	0.96	0.98	0.53
Property Plant And Equipment Net	0.98	-0.78	0.98	0.97	0.97	0.98		-0.96	-0.85	0.88	0.98	1.0	0.77	0.97	-0.54	0.98	0.71	-0.6	0.99	-0.74	-0.39	0.97	0.66	0.97	0.99	0.54
Net Debt	-0.96	0.92	-0.93	-0.95	-0.89	-0.89	-0.96		0.84	-0.92	-0.99	-0.94	-0.75	-0.95	0.37	-0.91	-0.71	0.38	-0.93	0.68	0.11	-0.89	-0.67	-0.96	-0.92	-0.5
Retained Earnings	-0.77	0.75	-0.92	-0.91	-0.75	-0.78	-0.85	0.84		-0.85	-0.83	-0.86	-0.98	-0.75	0.71	-0.86	-0.95	0.56	-0.89	0.29	0.29	-0.75	-0.94	-0.75	-0.89	-0.84
Accounts Payable	0.82	-0.87	0.89	0.95	0.77	0.77	0.88	-0.92	-0.85		0.92	0.87	0.81	0.81	-0.47	0.85	0.66	-0.33	0.88	-0.56	-0.08	0.77	0.64	0.81	0.86	0.49
Cash	0.98	-0.88	0.94	0.96	0.94	0.93	0.98	-0.99	-0.83	0.92		0.97	0.74	0.98	-0.41	0.94	0.68	-0.45	0.95	-0.74	-0.21	0.94	0.63	0.98	0.95	0.47
Non Current Assets Total	0.97	-0.76	0.98	0.97	0.97	0.98	1.0	-0.94	-0.86	0.87	0.97		0.78	0.96	-0.58	0.99	0.72	-0.63	0.99	-0.72	-0.42	0.97	0.67	0.96	1.0	0.56
Non Currrent Assets Other	0.67	-0.65	0.85	0.86	0.66	0.7	0.77	-0.75	-0.98	0.81	0.74	0.78		0.65	-0.79	0.79	0.94	-0.59	0.83	-0.19	-0.33	0.66	0.94	0.65	0.82	0.83
Cash And Short Term Investments	1.0	-0.79	0.91	0.9	0.98	0.96	0.97	-0.95	-0.75	0.81	0.98	0.96	0.65		-0.39	0.92	0.63	-0.52	0.93	-0.82	-0.31	0.98	0.56	1.0	0.93	0.4
Net Receivables	-0.42	0.1	-0.61	-0.58	-0.53	-0.56	-0.54	0.37	0.71	-0.47	-0.41	-0.58	-0.79	-0.39		-0.6	-0.69	0.89	-0.63	0.14	0.78	-0.53	-0.65	-0.39	-0.62	-0.61
Common Stock Total Equity	0.94	-0.73	0.99	0.97	0.95	0.98	0.98	-0.91	-0.86	0.85	0.94	0.99	0.79	0.92	-0.6		0.72	-0.64	1.0	-0.67	-0.45	0.95	0.68	0.93	1.0	0.62
Common Stock Shares Outstanding	0.64	-0.62	0.78	0.76	0.63	0.66	0.71	-0.71	-0.95	0.66	0.68	0.72	0.94	0.63	-0.69	0.72		-0.56	0.75	-0.1	-0.29	0.63	0.99	0.63	0.76	0.88
Non Current Liabilities Total	-0.54	0.01	-0.6	-0.53	-0.68	-0.68	-0.6	0.38	0.56	-0.33	-0.45	-0.63	-0.59	-0.52	0.89	-0.64	-0.56		-0.64	0.41	0.95	-0.68	-0.46	-0.52	-0.65	-0.42
Other Current Assets	0.94	-0.75	1.0	0.98	0.95	0.97	0.99	-0.93	-0.89	0.88	0.95	0.99	0.83	0.93	-0.63	1.0	0.75	-0.64		-0.66	-0.43	0.95	0.71	0.93	1.0	0.62
Other Stockholder Equity	-0.81	0.47	-0.6	-0.61	-0.82	-0.76	-0.74	0.68	0.29	-0.56	-0.74	-0.72	-0.19	-0.82	0.14	-0.67	-0.1	0.41	-0.66		0.35	-0.82	0.0	-0.82	-0.66	0.15
Total Liab	-0.33	-0.26	-0.38	-0.29	-0.51	-0.51	-0.39	0.11	0.29	-0.08	-0.21	-0.42	-0.33	-0.31	0.78	-0.45	-0.29	0.95	-0.43	0.35		-0.51	-0.2	-0.31	-0.45	-0.24
Net Invested Capital	0.98	-0.66	0.92	0.89	1.0	0.99	0.97	-0.89	-0.75	0.77	0.94	0.97	0.66	0.98	-0.53	0.95	0.63	-0.68	0.95	-0.82	-0.51		0.55	0.98	0.96	0.43
Property Plant And Equipment Gross	0.57	-0.63	0.75	0.73	0.55	0.6	0.66	-0.67	-0.94	0.64	0.63	0.67	0.94	0.56	-0.65	0.68	0.99	-0.46	0.71	0.0	-0.2	0.55		0.56	0.71	0.93
Total Current Assets	1.0	-0.79	0.91	0.9	0.98	0.96	0.97	-0.96	-0.75	0.81	0.98	0.96	0.65	1.0	-0.39	0.93	0.63	-0.52	0.93	-0.82	-0.31	0.98	0.56		0.94	0.41
Capital Stock	0.95	-0.74	0.99	0.98	0.96	0.98	0.99	-0.92	-0.89	0.86	0.95	1.0	0.82	0.93	-0.62	1.0	0.76	-0.65	1.0	-0.66	-0.45	0.96	0.71	0.94		0.63
Non Current Liabilities Other	0.43	-0.48	0.68	0.63	0.43	0.53	0.54	-0.5	-0.84	0.49	0.47	0.56	0.83	0.4	-0.61	0.62	0.88	-0.42	0.62	0.15	-0.24	0.43	0.93	0.41	0.63

Click cells to compare fundamentals

Immuneering Corp Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immuneering Reconciled Depreciation vs Cost Of Revenue Analysis

Reconciled Depreciation vs Cost Of Revenue

Reconciled Depreciation vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Reconciled Depreciation

Cost Of Revenue

Immuneering Corp fundamental ratios Correlations

Immuneering Corp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Immuneering Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Capital Stock	+ 1.0	Non Current Assets Total

Cash	- 0.99	Net Debt
Non Currrent Assets Other	- 0.98	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Net Debt	- 0.96	Property Plant And Equipment Net
Net Debt	- 0.96	Total Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings